CoreWeave Pulls Back from Core Scientific, CORZ Stock Crash Extends to 24%
Following months of exuberant profits driven by takeover rumors, Core Scientific's stock is now rapidly collapsing as investors doubt the...
Quick overview
- Core Scientific's stock has plummeted nearly 25% in two weeks as the narrative surrounding its acquisition of CoreWeave collapses.
- The company's Q3 earnings report revealed a significant revenue drop, missing analyst estimates and raising concerns about its financial stability.
- Investor confidence has waned due to CoreWeave's lowered revenue forecast and the stalled $9 billion acquisition deal, highlighting management's struggles.
- With deteriorating technicals and weak earnings, analysts view Core Scientific's recent rise as a speculative bubble rather than a sustainable recovery.
After months of euphoric gains fueled by takeover speculation, Core Scientific’s stock is now unraveling fast as the CoreWeave acquisition narrative collapses under pressure and investors question the company’s shaky fundamentals.
From Soaring Heights to a Sudden Fall
Core Scientific (NASDAQ: CORZ) had been one of the market’s surprise comeback stories of 2025. After trading near $6 in April, the stock rocketed nearly 400% to touch an all-time high of $23.66 early last week, driven by optimism over a potential CoreWeave acquisition. But that rally has since turned into a rout — CORZ has now plunged roughly 25% in just two weeks, with shares sliding below $18.
The reversal came right after a doji candlestick appeared at the top of the uptrend — a classic warning of exhaustion. The 20-day moving average, once solid support, has now flipped to resistance. Bears are targeting the 50-day line, and a confirmed breakdown there could drag the stock to the $13.30 region, aligning with the 200-day average.
Momentum has clearly turned against the bulls, as optimism over a CoreWeave tie-up fades and profit-taking accelerates.
CoreWeave’s Hesitation Sparks Panic
The collapse in sentiment stems largely from CoreWeave’s apparent retreat from its ambitious acquisition plan. Initially seen as a catalyst for growth, CoreWeave’s partnership was expected to turbocharge Core Scientific and GPU-hosting capacity.
However, the mood soured after CoreWeave’s lower revenue forecast during its Q3 earnings. The AI infrastructure giant, itself heavily reliant on Nvidia’s ecosystem, signaled slower expansion ahead — and that ripple effect crushed confidence in Core Scientific’s prospects.
The proposed $9 billion deal between the two companies has effectively stalled. The lack of sufficient shareholder approval and growing resistance among institutional investors reveal deep divisions about Core Scientific’s direction. Markets reacted instantly, with CORZ shedding over 2% on the announcement day alone. The episode highlighted rising doubts over management’s ability to execute amid eroding trust and growing financial strain.
Earnings Underscore the Weakness
Core Scientific’s own Q3 report only amplified investor unease. Revenue plunged to $81.1 million from $95.4 million a year earlier — missing analysts’ estimates by a wide margin. Although net loss improved to $0.46 per share, the market wasn’t impressed.
A 6.6% gross margin, negative 75% return on assets, and a negative price-to-book ratio of -5.55 painted a grim financial picture.
Investors are now asking whether the company’s massive spending and debt-fueled growth model are sustainable in a tightening market where enthusiasm for AI and quantum infrastructure is fading fast.
Uncertain Path Ahead
While some optimists argue that CoreWeave’s involvement could still bolster long-term capacity, most analysts see mounting risks. The company’s dependence on a handful of large clients and partners leaves it dangerously exposed to any contract renegotiations or slowdowns.
With the acquisition in limbo, weak earnings, and deteriorating technicals, Core Scientific’s meteoric rise now looks more like a speculative bubble than a sustainable recovery. Unless management can rebuild confidence and stabilize margins, the stock’s recent highs could mark a long-term top.
CORZ Chart Weekly – The 50 SMA Held As Support
CoreWeave’s Role in Expansion
CoreWeave, which heavily relies on Nvidia’s GPU-powered infrastructure, was expected to accelerate Core Scientific’s growth through the proposed acquisition. but it seems the CoreWeave has pulled back after the lower revenue forecast released with Q3 earnings yesterday, which has hurt the CORZ stock too.
The aborted merger with CoreWeave, attributed partly to insufficient stockholder approval, underscores significant dissent among stakeholders. Market participants noticed almost immediately; stock prices dipped by 2.05%. Investors seem wary of how close ties were cut, thrusting uncertainties into the forefront. Besides, doubts over the valuation of the $9B CoreWeave deal instigated challenges. Institutional advisory firms and capital stakeholders showed hesitance as Core Scientific battles to justify its strategic direction. Management’s ability to pivot now comes under scrutiny, as observers expect transparency in navigating post-merger challenges. Without sufficient advocacy for higher stockholder votes, the standoff indicates increasing scrutiny from oversight entities.
Besides that, the lower CRWV earning show that the quantum industry has ran ahead of itself, so investors are pulling back from AI stocks. Core Scientific issued its Q3 earnings, reflecting a downward trajectory in revenue. Compared to last year’s $95.4M, they reported $81.1M, leading to a slumped investor confidence. The company noted a narrowing net loss of $0.46 per diluted share, better than the previous year’s $1.17. Despite improved earnings per share, markets reacted with cautious skepticism. A missed revenue target against FactSet’s $112.8M estimate further dampened sentiment. The company’s profitability ratios remain discouraging, with a gross margin barely hitting 6.6%. On top of that, key ratios like a -75.29% return on assets and a bleak price-to-book value of -5.55 portray financial struggles.
Investor Debate: Growth vs. Risk
While the potential deal with Core Scientific could enhance capacity and strengthen CoreWeave’s competitive edge, critics warn about the risks of over-reliance on a few key partners. Any changes to these relationships—or renegotiations of major contracts—could expose vulnerabilities. Investors are weighing whether the heavy spending and acquisition strategy will ultimately drive sustainable returns.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
Save